Clinical Study of Augmentin in G-U Tract Infection / 대한비뇨기과학회지

ABSTRACT

Augmentin is a formulation of amoxycillin trihydrate and potassium clavulanate, a fused beta-lactam molecule produced by the fermentation of straptomyces clavuligerus. Most clinically important resistance is due to the production by bacteria of antibiotic destroying enzymes. In the case of penicillins and cephalospolins these enzymes are termed beta-lactamse as they destroy the beta-lactam ring of these antibiotics completely inactivating them. The presence of clavulanic acid extends the spectrum of amoxycillin to include beta-lactamse producing strains of common pathogens such as Staphylococcus, H influenza, E. coli, Neisseria spp, Proteus spp, Salmonella and Shigella. On clinical study of Augmenting in the field of Genitourinary tract infection cases. We selected randomly 30 patients, 20 males and 10 females, age from 21 to 71, in the period from October, 1985 to February, 1986. Among the total 30 patients, 15 were uncomplicated urinary tract infection and 15 were complicated urinary tract infection. Of the 15 patients with uncomplicated urinary tract infection, 14 patients had not bacteriuria after therapy and 1 patient was not changed. The clinical efficacy rate was 93.4%. Of the 4 patients with persistent infection, 2 patients had resistant P. aeruginosa, and 2 patients had S marcescens persistantly. The clinical efficacy rate was 73.4%. In 2 cases, mild diarrhea was developed, but medication was not stopped. The liver and renal function were normal range before and after treatment.